首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   108篇
  免费   3篇
  国内免费   2篇
耳鼻咽喉   1篇
儿科学   4篇
妇产科学   1篇
基础医学   6篇
口腔科学   3篇
临床医学   5篇
内科学   17篇
皮肤病学   4篇
神经病学   3篇
特种医学   2篇
外科学   13篇
综合类   20篇
预防医学   7篇
眼科学   5篇
药学   6篇
中国医学   13篇
肿瘤学   3篇
  2022年   1篇
  2021年   2篇
  2020年   1篇
  2019年   15篇
  2018年   17篇
  2017年   6篇
  2016年   2篇
  2015年   2篇
  2014年   2篇
  2013年   4篇
  2012年   8篇
  2011年   6篇
  2010年   1篇
  2009年   4篇
  2008年   1篇
  2006年   2篇
  2003年   3篇
  2002年   6篇
  2000年   1篇
  1999年   1篇
  1996年   2篇
  1994年   1篇
  1991年   1篇
  1985年   4篇
  1984年   7篇
  1982年   4篇
  1981年   6篇
  1979年   1篇
  1976年   1篇
  1975年   1篇
排序方式: 共有113条查询结果,搜索用时 15 毫秒
1.

Background

Persistent iatrogenic atrial septal defect (iASD) is a common but poorly characterized complication after cryoballoon (CB) pulmonary vein isolation (PVI) procedures. We therefore investigate its prevalence, evolution, risk factors, and clinical outcomes in a prospective longitudinal study.

Methods

A total of 108 patients (41 women, mean age 57 ± 11.3) underwent CB PVI for AF. Serial transesophageal echocardiography (TEE) was performed 9 months and then annually until 6 years after the procedure to study the characteristics of persistent iASD.

Results

Persistent iASD occurred in 33 (30.6%) patients 9 months after CB PVI. Spontaneous closure of iASD was found in 6 (22.2%) and 3 (15.8%) patients 2 and 3 years after the procedures, respectively. No spontaneous closure was observed on 4, 5, and 6-year TEE follow-up. The projected long-term persistence rate of iASD after CB PVI was therefore 20% (30.6% × 0.778 × 0.842). Using multivariate logistic regression, a higher number of cryoapplications (≥ 2 minutes) was the only independent predictor of persistent iASD 9 months after CB PVI (odds ratio [OR] 1.207; 95% confidence interval [CI], 1.033-1.411, P = 0.018). Two (1.9%) patients with significantly larger iASD size than the others (long diameter 12.6 ± 0.8 vs 3.7 ± 1.5 mm, P < 0.001; short diameter 10.9 ± 0.2 vs 3 ± 1.1 mm, P < 0.001) required percutaneous closure because of exertional dyspnea and right ventricular enlargement. Over 129.7 patient-years follow-up, during which iASD persisted, there was no occurrence of neurologic events.

Conclusions

Approximately one fifth of patients undergoing CB PVI will have permanently persistent iASD. Patients with defect sizes of greater than 10 mm may need percutaneous closure due to significant left-to-right shunting.  相似文献   
2.
3.
4.
5.

Objective

To describe indications and outcomes of patients fitted with the EyePrintPRO therapeutic scleral lens.

Methods

A database search of patients fitted with the EyePrintPRO from 2014 to 2016. Fourteen eyes of 10 patients were reviewed retrospectively. Patient demographics, medical and ocular history, indications for fitting, duration of wear, symptoms, and best-corrected visual acuity (BCVA) were analyzed.

Results

Mean age at lens fitting was 49 years (range, 21–67 years). The average duration of wear was 12 months (range, 7–17 months). Indications for fitting included limbal stem cell deficiency, post–photorefractive keratectomy (PRK) decentred ablation, pellucid marginal degeneration, Stevens-Johnson syndrome, keratoconus, dry eye, neurotrophic keratitis, exposure keratitis from facial nerve paralysis, and post–radial keratotomy (RK) symptoms. Mean BCVA was 20/36 (range, 20/20–20/200). After the fitting, mean BCVA was 20/21 (range 20/10–20/60, p = 0.001). Nine patients reported resolution of their blurry vision, and all reported improvement of dry eye, eye redness, and pain symptoms. Six of 7 previous lens wearers reported significantly greater comfort with EyePrintPRO wear and the ability to wear the lens throughout the day; only 2 experienced fogging and needed to clean the lens after 4–6 hours of wear.

Conclusions

A variety of indications for the EyePrintPRO scleral lens exist, and patients experience resolution of major symptoms. The ophthalmologist should be aware that therapeutic scleral lenses, including the EyePrintPRO, exist for patients for whom there is no surgical intervention or who want to delay or obviate the need for surgery.  相似文献   
6.
用心复康Ⅰ号作了小鼠急性毒性及耐缺氧实验。实验证明心复康Ⅰ号对常压耐缺氧、异丙肾上腺素引起的心肌耗氧量增加,亚硝酸钠、氰化钾中毒及结扎双侧颈总动脉的脑缺血缺氧均有明显地保护作用,把原中药复方煎剂经剂型改造成口服液其药理活性不变。  相似文献   
7.
目的:探讨禅宗"指月"之喻与《医古文》启发式教学的关系。方法:引述禅宗经典与启发式教学进行比较。结果与结论:禅宗"指月"之喻与《医古文》之启发式教学有异曲同工之妙。  相似文献   
8.
目的观察益髓除颤汤加服小剂量左旋多巴和左旋多巴治疗帕金森氏病的疗效。方法采用随机开放对照方法,将60例患者随机按2:1比例分为两组,治疗组40例,用自拟益髓除颤汤加小剂量左旋多巴;对照组20例,单纯用左旋多巴常规治疗,1月为一疗程,3个疗程后评定疗效。结果治疗组总有效率97.50%。对照组85.00%。治疗组明显优于对照组(P<0.05)。两组治疗前后症状、体征对比,治疗组优于对照组(P<0.05),药物副反应治疗组低于对照组。结论自拟益髓除颤汤加小剂量左旋多巴较单纯用左旋多巴治疗帕金森氏病,疗效确切,副作用小,症状缓解快。  相似文献   
9.
Dr.Yeh-chong Chan (Y.C.Chan) is one of the earliest acupuncturists in the United States (US).He served for seven years in the first acupuncture center in the US,which was established in Washington,D.C.in 1972.In 1979,he moved the clinic to Rockville,Maryland and continued to practice acupuncture there for over 30 years.He is a well-known licensed acupuncturist (LAc),one of the developers of the acupuncture profession,and a scholar of acupuncture and traditional Chinese medicine (TCM).He has treated two US Governors (In the US,the title Governor refers to the chief executive of each state or insular territory and the political and ceremonial head of the state.) and many sports stars.He is the author of books entitled Acupuncture Practice in the United States [1],Dr.Chan's Cancer Healing,Prevention and Self-healing and others.To record the early history of acupuncture in the US,on September 30,2012,the author,Dr.Arthur Fan interviewed Dr.Chan,70 years old,who is still in practice.  相似文献   
10.
[ 目的]《百济新集方》是东医最古医学文献之一.其方两首出自日本·丹波康赖撰《医心方》.本文就界定其问世年代为目的.[ 方法]《医心方》录有的《百济新集方》分别为黄耆治肺痈方、菊花治疔肿毒气入心欲困死方.在中医文献中考察这两首方,并以究其传播到百济的年代的方法进行.[ 结果]《医心方》所录《百济新集方》的两首方,均是《肘后方》的基础上产生的方.梁·大同七年,百济遣使梁求过经疏及医工.梁代有《肘后方》等132 种医书.[ 结论]《百济新集方》问世年代,是相当于梁·大同七年至隋开国之前的百济圣王明衤农十九年( 公元541 年) 至威得王昌二十七年( 公元580 年) 间.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号